You’ve decided to seek evaluation for treatment-resistant depression (TRD). You’ve scheduled the consultation. Now you’re wondering: What will they ask? What should you bring? How long will it take? What happens after?
A comprehensive treatment-resistant depression consultation typically lasts 45-90 minutes and includes detailed review of your treatment history, assessment of current symptoms using standardized rating scales, evaluation of comorbid conditions, and discussion of treatment options appropriate for your specific situation (McIntyre et al., 2019). The goal isn’t just diagnosing treatment-resistant depression—it’s understanding why standard treatments haven’t worked for you and identifying approaches that address your specific neurobiology.
Understanding what happens during this consultation helps you prepare effectively and reduces anxiety about an unfamiliar process.
What Information You’ll Need to Provide
The most valuable thing you can bring to your consultation is detailed documentation of your treatment history. Providers evaluating treatment-resistant depression need specific information that general intake forms don’t always capture.
For each antidepressant you’ve tried, your provider needs to know: the medication name and class, starting dose and maximum dose reached, how long you stayed at the maximum dose, what response you experienced (if any), what side effects occurred, and why you stopped taking it. “I tried Zoloft and it didn’t work” is insufficient—your provider needs to know whether you took 25mg for three weeks or 200mg for twelve weeks, because those represent completely different trials (Gaynes et al., 2020).
This documentation matters because inadequate trials account for a significant percentage of apparent treatment resistance. If you took therapeutic doses for adequate duration and genuinely didn’t respond, that pattern suggests you need alternative mechanisms. If your trials were inadequate—low doses, insufficient duration, or complicated by side effects—that pattern suggests different next steps.
At Allevate Health in Princeton, board-certified emergency medicine physicians with 18 years of medical practice experience review treatment histories to distinguish between genuine treatment resistance requiring ketamine-based approaches and situations where optimizing standard treatments might still provide relief. This distinction shapes your entire treatment plan, so accurate history is essential.
Beyond medication history, your provider will ask about psychotherapy experiences, medical conditions that might affect treatment response (thyroid problems, chronic pain, sleep disorders), family history of depression and treatment response, substance use, and current life stressors. Each factor helps build a complete picture of why standard treatments haven’t worked and what might work better.
The Clinical Assessment Process
Your consultation will include formal assessment of your current depression severity using standardized rating scales. These aren’t bureaucratic checkboxes—they establish baseline measurements that help track whether treatments are working.
Common assessment tools include the Hamilton Depression Rating Scale (HAM-D) or Montgomery-Åsberg Depression Rating Scale (MADRS), which evaluate depression severity across multiple symptom domains: mood, sleep, appetite, energy, concentration, anhedonia, suicidal thoughts, and physical symptoms. Your scores on these scales help determine whether you meet criteria for treatment-resistant depression and provide objective measures for tracking improvement (Gaynes et al., 2020).
Your provider will assess for conditions that can complicate treatment or mimic treatment resistance. Bipolar disorder often presents initially as depression, but antidepressants alone typically don’t work well for bipolar depression—so someone with unrecognized bipolar disorder may appear “treatment-resistant” when they actually need mood stabilizers. Similarly, untreated anxiety disorders, PTSD, or substance use can limit antidepressant response. Comprehensive evaluation identifies these factors.
Medical screening is also important. Thyroid dysfunction, vitamin D deficiency, anemia, and other medical conditions can contribute to treatment-resistant depression. Some medications prescribed for physical health conditions can worsen depression or interfere with antidepressant effectiveness. Your provider may recommend medical testing if these factors haven’t been ruled out already.
This thorough assessment takes time but provides the foundation for effective treatment planning. At Allevate Health, complimentary consultations ensure that financial concerns don’t prevent you from receiving comprehensive evaluation to determine whether ketamine therapy or other specialized approaches are appropriate for your situation.
Understanding Treatment Resistance Criteria
During your consultation, your provider will determine whether you meet clinical criteria for treatment-resistant depression. The standard definition requires failure to respond adequately to at least two antidepressant trials from different pharmacological classes, each given at adequate dose for sufficient duration (McIntyre et al., 2019).
“Adequate dose” means reaching the therapeutic range for that specific medication—not just the starting dose. “Sufficient duration” typically means 8-12 weeks at that therapeutic dose, not counting the titration period. “Different pharmacological classes” means trying medications with different mechanisms—an SSRI and an SNRI count as different classes, but two different SSRIs may not fully satisfy criteria depending on how strictly it’s applied.
Your provider will also assess the quality of your response to treatments. Did you experience no improvement at all? Partial improvement that wasn’t sufficient? Initial improvement that faded? Each pattern provides information about what’s happening in your brain and which treatments might work differently.
Some patients meet criteria for treatment-resistant depression by strictly defined standards. Others have complicated histories—multiple trials but some at inadequate doses or durations, or trials complicated by intolerable side effects before reaching therapeutic levels. Your provider will interpret your specific history to determine whether you’re truly treatment-resistant or whether optimization of standard approaches might still be appropriate.
This distinction matters because treatment recommendations differ. If you’re genuinely treatment-resistant, approaches like ketamine therapy—which work through glutamate mechanisms rather than the serotonin pathways that haven’t helped you—become highly relevant. If your trials were inadequate, completing proper trials of standard treatments may be more appropriate first steps.
Discussion of Treatment Options Appropriate for Your Situation
Based on your assessment, your provider will discuss treatment options suited to your specific presentation of treatment-resistant depression. This conversation should be comprehensive but personalized—not every treatment is appropriate for every patient.
For patients with genuine treatment resistance who have completed adequate trials without success, treatment options often include ketamine-based approaches, augmentation strategies, or intensive therapies. Your provider will explain which options you’re a candidate for based on your medical history, current medications, and symptom profile (Voineskos et al., 2020).
At Allevate Health in Princeton, New Jersey, treatment options for qualifying patients include three ketamine-based approaches: IV ketamine therapy ($600 per infusion, typically 6 sessions over 2-4 weeks), FDA-approved SPRAVATO® (esketamine nasal spray, often covered by insurance when criteria are met), and ketamine-assisted psychotherapy (combining ketamine infusions with therapeutic integration). Your provider will explain which approach best fits your clinical needs and practical circumstances.
This discussion should include expected timelines (“IV ketamine often produces effects within hours to days, with full benefit building over the initial series”), what the treatment process involves, potential side effects, and realistic outcome expectations. Ketamine therapy shows approximately 70% response rates in treatment-resistant depression—which is encouraging but not guaranteed. Results vary by individual, and comprehensive discussion helps you understand both possibilities and limitations.
Your provider should also address practical considerations: costs and insurance coverage, scheduling requirements, transportation needs (you cannot drive after ketamine sessions), and how ketamine therapy integrates with your other mental health care. These practical factors significantly affect whether a treatment is realistically feasible for you.
Questions You Should Ask During Your Consultation
Come prepared with specific questions that help you make informed decisions about your care. Important questions include:
About your diagnosis: “Based on my history, do I meet criteria for treatment-resistant depression? Were my previous medication trials adequate, or were there issues with dose or duration that might have limited response?” This helps you understand whether you need alternative approaches or whether optimization of standard treatments remains appropriate.
About treatment recommendations: “Why are you recommending this specific treatment for my situation? What evidence supports its use for someone with my treatment history? What are realistic expectations for improvement—complete remission or meaningful but partial relief?” These questions ensure recommendations are based on your specific situation rather than generic protocols.
About the treatment process: “What does the treatment process involve day-to-day? How long before I might notice effects? How will we measure whether it’s working? What happens if this approach doesn’t work?” Practical process questions help you plan logistics and understand what to expect.
About costs and access: “What will this cost? Is it covered by insurance? Are payment plans available? How long do I have to commit to treatment before we can assess whether it’s helping?” Financial clarity prevents surprises that could interrupt your treatment.
At Allevate Health, providers address these questions during complimentary consultations, ensuring you have complete information before deciding whether to proceed with ketamine therapy. No one should start treatment without understanding costs, process, and realistic expectations.
What Happens After the Consultation
Following your comprehensive assessment, several outcomes are possible depending on what the evaluation reveals.
If you’re an appropriate candidate for specialized treatment: Your provider will discuss starting treatment, explain the protocol (for ketamine: typically beginning with 6 infusions over 2-4 weeks), schedule your first session, and provide preparation instructions. For SPRAVATO®, your provider may need to submit prior authorization to your insurance before beginning treatment.
If further evaluation is needed: Your provider may recommend medical testing (thyroid function, vitamin D levels, etc.), consultation with other specialists, or addressing comorbid conditions before proceeding with specialized treatment. These additional steps ensure you’re getting appropriate comprehensive care rather than pursuing expensive interventions that might not work if underlying factors aren’t addressed.
If standard treatments haven’t been adequately tried: Your provider may recommend optimizing traditional approaches first—completing adequate trials at therapeutic doses, trying augmentation strategies, or addressing factors that may have limited previous treatment response. This doesn’t mean you’ll never be a candidate for ketamine therapy, but it means optimizing less invasive options makes sense as a next step.
Regardless of the specific recommendation, you should leave your consultation with clear understanding of why specific approaches are recommended for your situation, what the next steps are, and what timeline to expect. If anything remains unclear, ask for clarification before leaving—understanding your treatment plan is essential for following through effectively.
Preparing for Your Consultation: Practical Steps This Week
- Create your detailed medication history document. Make a spreadsheet or list including every antidepressant you’ve tried, with columns for: medication name, dates taken, starting dose, maximum dose reached, total time at maximum dose, what you noticed (improvements, side effects), and why you stopped. If you can’t remember exact doses or dates, approximate as best you can. This documentation is the single most valuable thing you can bring to your consultation.
- Gather relevant medical records. Request records from previous psychiatrists or primary care providers who prescribed antidepressants. While not always necessary, having documentation of previous trials can clarify questions about adequacy of dose or duration. If getting records is difficult, don’t let that delay your consultation—your detailed history is more important than official paperwork.
- Write down your questions and priorities. Before your consultation, list what you most want to know. Are you primarily concerned about costs? Timeline to improvement? Treatment process? Side effects? Knowing your priorities helps your provider address your most important concerns even if time is limited.
Addressing Common Concerns About TRD Specialized Consultations
Many patients hesitate to schedule consultations for treatment-resistant depression due to specific concerns. Understanding these common worries helps you move forward despite anxiety about the process.
“What if they just tell me to try another antidepressant?” Providers specializing in treatment-resistant depression understand that if you’ve completed multiple adequate trials, trying more medications within the same mechanisms has diminishing returns. While they may suggest optimization if your previous trials were inadequate, they won’t simply prescribe another SSRI if you’ve genuinely exhausted serotonin-targeted approaches.
“I’m worried about the cost if insurance doesn’t cover treatment.” This is a legitimate concern. Upfront cost discussion during your consultation ensures you have complete information before committing. At Allevate Health, IV ketamine infusions cost $600 per session, with payment plans available through Advanced Care. SPRAVATO® may be covered by insurance if you meet criteria. Knowing costs before starting treatment allows you to make informed decisions about whether specialized approaches are financially feasible right now.
“What if I go through this evaluation and don’t qualify for treatment?” Comprehensive evaluation always has value, even if the outcome is that you’re not an appropriate candidate for specialized treatment right now. The evaluation might identify factors limiting your treatment response that can be addressed, suggest alternative approaches you haven’t tried, or confirm that you have been receiving appropriate care and need to give current treatments more time. Understanding your situation more clearly is worthwhile regardless of whether specialized treatment is immediately recommended.
Moving Forward with Clarity
Your first consultation for treatment-resistant depression is primarily an information-gathering and planning session—not an immediate treatment decision. The goal is understanding your specific situation thoroughly enough to make informed recommendations about next steps.
At Allevate Health in Princeton, New Jersey, complimentary consultations with board-certified emergency medicine physicians provide comprehensive evaluation without financial barrier. During these consultations, we review your complete treatment history, assess current symptoms, determine whether you meet criteria for treatment-resistant depression, and discuss whether ketamine-based approaches—IV therapy, SPRAVATO®, or ketamine-assisted psychotherapy—are appropriate for your specific situation.
You’ll leave your consultation with clear understanding of your diagnosis, why previous treatments haven’t worked adequately, what treatment options you’re a candidate for, and what realistic expectations are for different approaches. Whether you proceed with specialized treatment immediately, pursue additional evaluation, or optimize standard approaches first, you’ll have roadmap for moving forward based on comprehensive assessment rather than trial-and-error.
To schedule a complimentary consultation at Allevate Health, call 640-252-9785 or visit allevatehealth.com. Our Princeton location serves patients throughout central New Jersey seeking evaluation and treatment for depression that hasn’t responded adequately to standard approaches.
References
Gaynes, B.N., Lux, L., Gartlehner, G., Asher, G., Forman-Hoffman, V., Green, J., Boland, E., Weber, R.P., Randolph, C., Bann, C., Coker-Schwimmer, E., Viswanathan, M., & Lohr, K.N. (2020). Defining treatment-resistant depression: A comprehensive review. Depression and Anxiety, 37(2), 134-145. https://onlinelibrary.wiley.com/doi/full/10.1002/da.22968
McIntyre, R.S., Alsuwaidan, M., Baune, B.T., Berk, M., Demyttenaere, K., Goldberg, J.F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S.H., Ly-Uson, J., Mansur, R.B., McAllister-Williams, R.H., Murrough, J.W., Nemeroff, C.B., Nierenberg, A.A., Rosenblat, J.D., Sanacora, G., Schatzberg, A.F., Shelton, R., Stahl, S.M., Trivedi, M., Vieta, E., Vinberg, M., Young, A.H., Zarate, C.A., & Mansur, R.B. (2019). Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders, 156, 1-7. https://www.sciencedirect.com/science/article/abs/pii/S0165032718324801
Voineskos, D., Daskalakis, Z.J., & Blumberger, D.M. (2020). Management of treatment-resistant depression: Challenges and strategies. Neuropsychiatric Disease and Treatment, 16, 221-234. https://www.dovepress.com/management-of-treatment-resistant-depression-challenges-and-strategies-peer-reviewed-fulltext-article-NDT